Vertex Pharmaceuticals Incorporated (VRTX) : On Monday, The money flowed into the Vertex Pharmaceuticals Incorporated (VRTX) stock with an uptick to downtick ratio was recorded at 2.29. Transactions worth $40.88 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $17.88 million. The total money flow into the stock was $23 million. The block trades reveal a bullish bias with an up-down ratio of 24.06. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $23.95 million of block transactions on upticks. The value of block trades on downticks was $1 million, indicating lower selling interest. The total money flow in block trades was $22.95 million. In terms of price action, Vertex Pharmaceuticals Incorporated (VRTX) traded down $0.79 during the session at $89.42. Compared to the previous days closing, the stock was down only by -0.88%. For the week, the stock is 0.52%, over previous weeks closing.
Vertex Pharmaceuticals Incorporated is up 7.45% in the last 3-month period. Year-to-Date the stock performance stands at -28.94%. Vertex Pharmaceuticals Incorporated has lost 0.75% in the last five trading days and dropped 1.1% in the last 4 weeks. In a related news, Boger Joshua S, director of Vertex Pharmaceuticals Inc / Ma, unloaded 6,500 shares at an average price of $89.07 on July 13, 2016. The total amount of the transaction was worth $578,955, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): On Mondays trading session , Opening price of the stock was $90.06 with an intraday high of $90.8. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $89.32. However, the stock managed to close at $89.42, a loss of 0.88% for the day. On the previous day, the stock had closed at $90.21. The total traded volume of the day was 1,127,156 shares.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.